Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of lazertinib vs gefitinib in EGFR-mutant advanced NSCLC
2019-004814-32Phase 3Active
- Sponsor
- Yuhan
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lazertinib in Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Yuhan. Primary endpoint: Progression-free survival. Started Jun 2020; status: active.
02
Drugs
lazertinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2019-004814-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004814-32.